Finding the Latent Treponema Pallidum
Study Details
Study Description
Brief Summary
Some syphilitic patients remain in a serologically positive state after the recommended therapy. Whether a serofast state could represent a persistent low-level infection by Treponema pallidum is still unknown. The possibility that persistent nontreponemal antibodies after treatment represent persistence of Treponema pallidum was raised by some investigators. The investigators use the Next-Generation Sequencing to test blood plasma, srum, cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast patient and other positive and negative controls.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Some syphilitic patients remain in a serologically positive state after the recommended therapy. Whether a serofast state could represent a persistent low-level infection by Treponema pallidum is still unknown. The possibility that persistent nontreponemal antibodies after treatment represent persistence of Treponema pallidum was raised by some investigators. The investigators use the Next-Generation Sequencing to test blood plasma, serum, cerebrospinal fluid, aqueous humor, lymph nodes, skin lesion, saliva, semen,milk of serofast patient and other positive and negative controls.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Serofast status The syphilitic patients who remain in a serologically positive state after therapy |
Diagnostic Test: RPR Titer
RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
|
Untreated untreated syphilis cases |
Diagnostic Test: RPR Titer
RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
|
Serological cure In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer. In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer. |
Diagnostic Test: RPR Titer
RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
|
Outcome Measures
Primary Outcome Measures
- the reads of treponema pallidum [30 days]
Using the Next-Generation Sequencing to test specific genome of treponema pallidum for syphilis
Eligibility Criteria
Criteria
Inclusion Criteria:
- All clinical diagnosis of syphilis cases
Exclusion Criteria:
-
Auto-immune disease (such as SLE)
-
Lyme disease
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | PekingUMCH | Beijing | China |
Sponsors and Collaborators
- Peking Union Medical College Hospital
Investigators
- Principal Investigator: Jun Li, Peking Union Medical College Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- The reaseon of serofast